Conference
RANDOMIZED, DOUBLE-BLIND PHASE II TRIAL OF CARBOPLATIN plus PACLITAXEL [C plus P] WITH EITHER DAILY ORAL CEDIRANIB, AN INHIBITOR OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR [VEGFR] TYROSINE KINASES, OR PLACEBO, IN ADVANCED NON-SMALL CELL LUNG CANCER [NSCLC]: A STUDY OF THE NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP
Authors
Laurie SA; Arnold A; Shepherd FA; Dediu M; Ciuleanu T; Fenton D; Zukin M; Goss G; Ding K; Seymour L
Volume
19
Pagination
pp. 90-91
Publisher
OXFORD UNIV PRESS
Publication Date
September 1, 2008
Name of conference
33rd European-Society-for-Medical-Oncology Congress
Conference place
Stockholm, SWEDEN
Conference start date
September 12, 2008
Conference end date
September 16, 2008
Conference proceedings
ANNALS OF ONCOLOGY
ISSN
0923-7534